CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7224 result(s)

Providing Appropriate Virtual Care Within and Beyond the Pandemic: Considerations for Policy-Makers

Event Date: May 5, 2021
Result type: Events

The COVID-19 pandemic has definitely affected many different aspects of the Canadian health care system — including the widespread adoption of virtual care. Demand for virtual care is unlikely to diminish over the immediate and long term; therefore, many people are wondering how to best optimize virtual care to ensure its sustainability and its ...

CADTH Lecture — How to Advance Gender Equity

Event Date: April 20, 2021
Result type: Events

Despite evidence showing that greater gender equity is better for health policy-making and patient care, gender inequity remains a problem in Canadian health care. This lecture will explore the occurrence and consequences of gender inequity in medicine and academia, present why gender equity is important, and provide strategies to promote gender...

upadacitinib (Rinvoq)

Last Updated: April 14, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: upadacitinib
Indications: RINVOQ is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. RINVOQ can be used with or without topical corticosteroids.​

  • Brand Name: Rinvoq
  • Manufacturer: AbbVie
  • Project Number: SR0685-000
  • Project Status: Received

inclisiran (TBC)

Last Updated: April 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: inclisiran
Indications: Inclisiran is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial), as an adjunct to diet: • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low density lipoprotein cholesterol (LDL-C) goals with the tolerated dose of a statin or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

  • Brand Name: TBC
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0681-000
  • Project Status: Active
  • Submission Type: Initial

human insulin (Entuzity KwikPen)

Last Updated: April 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: human insulin
Indications: ​To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

  • Brand Name: Entuzity KwikPen
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0672-000
  • Project Status: Active
  • Submission Type: Initial

brexucabtagene autoleucel (TBC)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: brexucabtagene autoleucel
Indications: For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi).

  • Brand Name: TBC
  • Manufacturer: Gilead Sciences Canada Inc.
  • Project Number: PG0219-000
  • Project Status: Active
  • Submission Type: Initial

encorafenib and binimetinib (Braftovi and Mektovi)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: encorafenib and binimetinib
Indications: ​Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.

  • Brand Name: Braftovi and Mektovi
  • Manufacturer: Pfizer Canada ULC
  • Project Number: PC0232-000
  • Project Status: Active
  • Submission Type: Initial

pembrolizumab (Keytruda )

Last Updated: April 14, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: pembrolizumab
Indications: ​First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.

  • Brand Name: Keytruda
  • Manufacturer: Merck Canada
  • Project Number: PC0250-000
  • Project Status: Pending
  • Submission Type: Initial

Workshop: Combining Different Types of Evidence on Effectiveness, Implementation, and Views to Better Understand Complex Interventions

Event Date: April 14, 2021
Result type: Events

Audience: Producers
Level: Intermediate What you’ll learn: Workshop participants will: 1) articulate the differences between traditional effectiveness reviews and mixed methods research syntheses (MMRS); 2) identify when an MMRS would be appropriate; 3) demonstrate an understanding of the different stages of MMRS. Dr. Quan Nha Hong, In...

tucatinib (Tukysa )

Last Updated: April 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: tucatinib
Indications: ​Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.

  • Brand Name: Tukysa
  • Manufacturer: Seagen Canada Inc.
  • Project Number: PC0243-000
  • Project Status: Active
  • Submission Type: Initial